A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in Combination with an Anti-PD-1 Antibody in Subjects with Advanced Solid Tumours.

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Spence, Anne (Project Manager)

Project: Research

Project Details

Effective start/end date24/02/2231/12/25


  • Medical oncology
  • Clinical trial